MX9704225A - Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora. - Google Patents

Fragmentos de anticuerpos monoclonales que tienen actividad inmunosupresora.

Info

Publication number
MX9704225A
MX9704225A MX9704225A MX9704225A MX9704225A MX 9704225 A MX9704225 A MX 9704225A MX 9704225 A MX9704225 A MX 9704225A MX 9704225 A MX9704225 A MX 9704225A MX 9704225 A MX9704225 A MX 9704225A
Authority
MX
Mexico
Prior art keywords
mab
fragments
monoclonal antibody
antibody fragments
immunosuppressant activity
Prior art date
Application number
MX9704225A
Other languages
English (en)
Other versions
MXPA97004225A (es
Inventor
Zoltan Nagy
Damir Vidovic
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX9704225A publication Critical patent/MX9704225A/es
Publication of MXPA97004225A publication Critical patent/MXPA97004225A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion consta de fragmentos mAb monovalentes (Fab) De mAb que tienen la capacidad de reducir la sensibilidad de la expresion del HLA-DR en células presentadoras del antígeno. Los fragmentos Fab pueden reducir la sensibilidad de dicha expresion del HLA-DR sin la citotoxicidad del mAb madre o de los fragmentos bivalentes (F(ab)'2) del mAb. Los fragmentos Fab de la invencion son por lo tanto potentes compuestos inmunosupresores específicos para el MHC de clase II, sin efectos citotoxicos colaterales.
MXPA/A/1997/004225A 1994-12-07 1997-06-06 Fragmentos de anticuerpos monoclonales que tienenactividad inmunosupresora MXPA97004225A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35091594A 1994-12-07 1994-12-07
US350915 1994-12-07
PCT/EP1995/004648 WO1996017874A1 (en) 1994-12-07 1995-11-25 Monoclonal antibody fragments having immunosuppressant activity

Publications (2)

Publication Number Publication Date
MX9704225A true MX9704225A (es) 1997-09-30
MXPA97004225A MXPA97004225A (es) 1998-07-03

Family

ID=

Also Published As

Publication number Publication date
FI972430A (fi) 1997-06-06
TR199501542A2 (tr) 1996-07-21
AU4256096A (en) 1996-06-26
JP2001506122A (ja) 2001-05-15
MA23739A1 (fr) 1996-07-01
AR002005A1 (es) 1998-01-07
CN1168679A (zh) 1997-12-24
IL116228A0 (en) 1996-03-31
CZ172497A3 (en) 1997-10-15
NO972522L (no) 1997-08-06
BR9509902A (pt) 1997-10-21
FI972430A0 (fi) 1997-06-06
NO972522D0 (no) 1997-06-03
EP0787151A1 (en) 1997-08-06
HUT77342A (hu) 1998-03-30
PE52996A1 (es) 1996-12-12
PL320610A1 (en) 1997-10-13
ZA9510195B (en) 1996-06-07
WO1996017874A1 (en) 1996-06-13
CO4480041A1 (es) 1997-07-09
CA2206471A1 (en) 1996-06-13

Similar Documents

Publication Publication Date Title
ATE208820T1 (de) Humanisierte antikoerper
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
HK1044159A1 (zh) 抗γ-干擾素的人化抗體
AU6726698A (en) Use of interleukin-15
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0866133A3 (en) A group b streptococcus vaccine
CA2212150A1 (en) Monoclonal antibodies for human osteogenic cell surface antigens
BR9711306A (pt) Amino a-Úcar citotÄxico e derivados de a-Úcar correlatos de indolopirrolocarbazÄis
AU3407197A (en) Purified sperm surface antigen, monoclonal antibody therefor and applications therefor
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
HK1016017A1 (en) Gonococcal anti-idiotypic antibodies and methods and compositions using them
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DE69007799D1 (de) Pharmazeutische antigen-antikörper-komplexe enthaltende zusammensetzungen und deren anwendungen.
WO1997025071A3 (en) Immunoconjugate for the treatment of aids
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
AU7160691A (en) Monoclonal antibodies which neutralize hiv-1 infection and their anti-idiotypes
DE69333952D1 (de) Klonering von dem gen für das t gondii protein gp 28.5 peptidfragmente aus diesem protein und ihre verwendungen.
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
ZA971403B (en) Tumor rejection antigens presented by HLA-B44 molecules, and uses thereof.
EP1028754A4 (en) PREVENTION OF IMMUNE REACTIVITY DUE TO DEPTH OR INHIBITION OF ANTIGENT PRESENTING CELLS
AU4441393A (en) Granulocyte-binding antibody fragments, their preparation and use
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
WO1992004464A3 (en) Monoclonal antibodies against tenascin
IL122011A0 (en) Human beta 2 integrin alpha subunit
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof